Compare PERI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | CLLS |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 476.5M |
| IPO Year | 2006 | 2007 |
| Metric | PERI | CLLS |
|---|---|---|
| Price | $9.51 | $4.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $14.75 | $8.50 |
| AVG Volume (30 Days) | ★ 265.1K | 114.5K |
| Earning Date | 02-18-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,361,000.00 | $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $8.59 | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $7.00 | $1.10 |
| 52 Week High | $11.79 | $5.48 |
| Indicator | PERI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 46.07 |
| Support Level | $9.30 | $4.62 |
| Resistance Level | $9.79 | $4.97 |
| Average True Range (ATR) | 0.24 | 0.25 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 25.00 | 41.18 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.